Tokyo IPO

Japanese

K Pharma,Inc.

Code Sector Market
4896 Pharmaceuticals Growth
Date of listing approval 2023/09/12
Expected Date 2023/10/17
Lead Underwriter SBI SECURITIES Co.,Ltd.    
Description  
Listed Shares(total) 1,932,000
Trading Unit 100
New Shares 1,680,000
Existing Shares 252,000¡Êonly O.A.¡Ë
Shares Outstanding PreIPO 9,879,000.00
PostIPO 11,559,000.00
Paid Up Capital PreIPO Y100,000,000
PostIPO Y642,360,700
Expected Pricing Date 2023/09/27
Book Building Start 2023/09/29
Book Building End 2023/10/05
Fix Date 2023/10/06
Offering Starts 2023/10/10
Offering Ends 2023/10/13
Expect Pricing Y900-Y1,040
Notional PER
(based on previous period)
-21.40--24.73
Notional PER(based on results forecast) 50.88-58.79
Offering Price Y950
Offering Price PER
(based on previous period)
50.88-58.79
Offering Price PBR
(based on previous period)
-7.74
Offering Price PER
(based on results forecast)
53.70
Use of Funds Raised  

Financial Data

Units:Y1,000

Fiscal Year End:2020/12
Consolidated Non-consolidated
Revenue - -
Current Profit - -269,562
Net Profit - -271,219
Net Assets - 8,009
Fiscal Year End:2021/12
Consolidated Non-consolidated
Revenue - -
Current Profit - -220,892
Net Profit - -228,718
Net Assets - 178,891
Fiscal Year End:2022/12
Consolidated Non-consolidated
Revenue - -
Current Profit - -359,233
Net Profit - -392,427
Net Assets - 1,336,263
Recent Quarter
2023/06
Consolidated Non-consolidated
Revenue - 1,000,000
Current Profit - 651,026
Net Profit - 514,772
Net Assets - 1,851,036
Results Forecast
2023/12
Consolidated Non-consolidated
Revenue - 1,000,000
Current Profit - 266,000
Net Profit - 180,000
Net Assets - -

Per Share Units:Y1

Fiscal Year End:2020/12
Consolidated Non-consolidated
Dividend 0.00
Net Earning - -
Equity -38.75 -84.54
Fiscal Year End:2021/12
Consolidated Non-consolidated
Dividend 0.00
Net Earning - -
Equity -30.09 -107.03
Fiscal Year End:2022/12
Consolidated Non-consolidated
Dividend 0.00
Net Earning - -
Equity -42.06 -122.77
Fiscal Year End:Interim Results
2023/06
Consolidated Non-consolidated
Dividend  
Net Earning - 52.11
Equity - -
Fiscal Year End:Results Forecast
2023/12
Consolidated Non-consolidated
Dividend 0.00
Net Earning - 17.69
Equity - -

Comment

¢£Over allotment(252,000)

Consolidated Subsidiaries

Name Address

Underwriters

Allocation Underwriter Tel
0% Nomura 03-3211-1811
85% SBI SECURITIES Co.,Ltd. 03-5562-7210
10% Okasan 03-3272-2211
3% SMBC Nikko 03-5644-3111
1% IwaiCosmo Securities Co.,Ltd. 06-6229-2890
0.5% Kyokuto 03-3667-9171
0.3% Matsui 03-5216-0606
0.2% Rakuten Securities 03-6406-2681

Data

Date of incorporation 2016/11/01
Company address  Tokyo 106-0032
Telephone 03-6629-3380
President  
Homepage https://www.kpharma.co.jp/
Auditor Azsa
Major Shareholders
Shareholder Name Ratio
86.62%
  22.03%
  13.71%
  11.59%
  11.59%
  10.34%
  6.47%
  5.88%
  5.80%
  4.97%
  2.26%
Number of Employees 16 as of 2023/08/31
Birth Date of Representative 1960/07/30

Comment